Biogen boosts Aduhelm confirmatory trial amid fight for wider Medicare coverage | Fierce Pharma
After disastrous start to launch, Biogen still expects 'minimal' sales from Aduhelm this year | Fierce Pharma
The Science of Aging: Summer 2020 – The Science of Aging
New Disease Modifying Drug for Alzheimer's Disease Fully Approved by FDA, Highlighting the Crucial Role for Cognetivity in Early Detection and Monitoring - Cognetivity
Biogen Plans Regulatory Filing for Aducanumab in Alzheimer's Disease Based on New Analysis of Larger Dataset from Phase 3 Studies | Biogen
The Future of Alzheimer's Treatment? Approval of Aduhelm & Other Anti-Amyloid Antibodies – Montgomery County Medical Society
Biogen Beats Earnings Expectations but Leaves CFO's Departure a Mystery | Barron's
NEWS RELEASE - Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer's Disease
Aduhelm Medicare coverage: US prospects for contentious AD drug
Biogen and Neurimmune Announce Option Exercise for Alzheimer's Disease Investigational Treatment Aducanumab | Business Wire
Public comment
Biogen strikes back at investor lawsuit on Aduhelm launch flop
Assessing How Much an Alzheimer's Drug is Worth
Aduhelm (aducanumab) Q+A - Penn Memory Center
Eisai and Biogen announce positive Phase 3 results for lecanemab - UCI MIND
Positive functional results reported for aducanumab in a pooled, post hoc analysis | MDedge Internal Medicine
Biogen's Alzheimer's Drug Faces a Big Test. What to Know. | Barron's
Biogen Scraps Sales Support for Alzheimer Therapy Aduhelm in US
FDA Delays Aducanumab Decision | Being Patient
Patient receives first infusion of Biogen's controversial Alzheimer's drug
Concerns grow over safety of Aduhelm after death of patient who got the drug - The Boston Globe
Data dredging or a $50B drug: an intro to interpreting clinical data
EMA gives thumbs down to Biogen's Alzheimer's drug aducanumab - Drug Discovery and Development
James Deardorff on Twitter: ""Biogen Plans Regulatory Filing for Aducanumab in Alzheimer's Disease" - Hmm... 1. https://t.co/k7Ga4ja0br 2. https://t.co/5cr8gYW72s https://t.co/7NboyUVjWr" / Twitter
U.S. Veterans Health Administration turns down Biogen Alzheimer's drug | Reuters
FDA's Approval of Biogen's New Alzheimer's Drug Has Huge Cost Implications for Medicare and Beneficiaries - KFF | KFF
Biogen Loses $18B in Value as It Kills Aducanumab Alzheimer's Program | BioSpace
Will Insurers Pay for New Alzheimer's Drug? | MedPage Today
